Page 12 - PACE: Advanced Prostate Cancer Consensus

Management of Patients with nmCRPC

• Prior to 2018, there was no effective standard of care

• Starting in 2018 and into 2019, three major studies

demonstrated a marked benefit in delaying metastasis

with AR inhibitor + ADT

• Apalutamide (+ ADT): SPARTAN

• Enzalutamide (+ ADT): PROSPER

• Darolutamide (+ ADT): ARAMIS

AR, androgen receptor; ADT, androgen deprivation therapy